Literature DB >> 19368833

Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus.

Katherine W Falenski1, Dawn S Carter, Anne J Harrison, Billy R Martin, Robert E Blair, Robert J DeLorenzo.   

Abstract

Several reports have focused on the involvement of the endocannabinoid system in hyperexcitability, particularly in seizure and epilepsy models. Our laboratory recently characterized a novel plasticity change of the cannabinoid type 1 (CB(1)) receptor in hippocampi of epileptic rats following pilocarpine-induced status epilepticus (SE). This long-term redistribution included selective layer-specific changes in CB(1) receptor expression within distinct hippocampal subregions. However, the temporal characteristics of this redistribution during the development of epilepsy had not been examined. Therefore, this study was initiated to evaluate the time course by which pilocarpine-induced SE produced changes in CB(1) receptor expression. Immunohistochemical analysis demonstrated that within 1 week following SE, there was a pronounced loss in CB(1) receptor expression throughout the hippocampus, while staining in many interneurons was preserved. By 1 month post-SE, pilocarpine-treated animals began to display epileptic seizures, and CB(1) receptor expression was characteristic of the redistribution observed in long-term epileptic rats, with decreases in CB(1) receptor immunoreactivity in the stratum pyramidale neuropil and dentate gyrus inner molecular layer, and increases in the strata oriens and radiatum of CA1-3. Observed changes in CB(1) receptor expression were confirmed at multiple time points by western blot analysis. The data indicate that overall decreases in expression following SE preempt a long-lasting CB(1) receptor redistribution, and that differential responses occur within the hippocampus to initial CB(1) receptor losses. This suggests a role for dysregulation of the endocannabinoid system during epileptogenesis and indicates that the CB(1) receptor redistribution temporally correlates with the emergence of epileptic seizures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368833      PMCID: PMC2841984          DOI: 10.1016/j.brainres.2009.01.036

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  38 in total

1.  Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

3.  Loss of interneurons innervating pyramidal cell dendrites and axon initial segments in the CA1 region of the hippocampus following pilocarpine-induced seizures.

Authors:  Celine Dinocourt; Zdravko Petanjek; Tamas F Freund; Yezekiel Ben-Ari; Monique Esclapez
Journal:  J Comp Neurol       Date:  2003-05-12       Impact factor: 3.215

4.  Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain.

Authors:  G Marsicano; B Lutz
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

5.  Chronic DeltaFosB expression and increased AP-1 transcription factor binding are associated with the long term plasticity changes in epilepsy.

Authors:  T A Morris; N Jafari; R J DeLorenzo
Journal:  Brain Res Mol Brain Res       Date:  2000-06-23

6.  Alterations of hippocampal GAbaergic system contribute to development of spontaneous recurrent seizures in the rat lithium-pilocarpine model of temporal lobe epilepsy.

Authors:  V André; C Marescaux; A Nehlig; J M Fritschy
Journal:  Hippocampus       Date:  2001       Impact factor: 3.899

7.  Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.

Authors:  M J Wallace; J L Wiley; B R Martin; R J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

8.  Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.

Authors:  Nima Naderi; Farzad Aziz Ahari; Bijan Shafaghi; Azadeh Hosseini Najarkolaei; Fereshteh Motamedi
Journal:  J Neural Transm (Vienna)       Date:  2008-06-25       Impact factor: 3.575

9.  Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.

Authors:  Melisa J Wallace; Billy R Martin; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2002-10-11       Impact factor: 4.432

10.  Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy.

Authors:  Masayuki Kobayashi; Paul S Buckmaster
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

View more
  20 in total

1.  Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.

Authors:  Katherine W Sayers; Peter T Nguyen; Robert E Blair; Laura J Sim-Selley; Robert J DeLorenzo
Journal:  Epilepsia       Date:  2012-04-17       Impact factor: 5.864

Review 2.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

Review 3.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

4.  Cannabidiol: promise and pitfalls.

Authors:  Timothy E Welty; Adrienne Luebke; Barry E Gidal
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 5.  Hippocampal GABAergic Inhibitory Interneurons.

Authors:  Kenneth A Pelkey; Ramesh Chittajallu; Michael T Craig; Ludovic Tricoire; Jason C Wester; Chris J McBain
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

6.  L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure.

Authors:  Nima Naderi; Leila Ahmad-Molaei; Ali Mazar-Atabaki; Abdolaziz Ronaghi; Zahra Shirazi-zand; Seyed Mehrdad Motiei-Langroudi; Somayeh Eslahkar
Journal:  Neurochem Res       Date:  2011-09-18       Impact factor: 3.996

Review 7.  Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention.

Authors:  Mackenzie E Hofmann; Charles J Frazier
Journal:  Exp Neurol       Date:  2011-12-09       Impact factor: 5.330

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics.

Authors:  Ying Yu; Lexiao Li; Davis T Nguyen; Suni M Mustafa; Bob M Moore; Jianxiong Jiang
Journal:  Mol Neurobiol       Date:  2020-05-06       Impact factor: 5.590

10.  Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy.

Authors:  Mária R Karlócai; Kinga Tóth; Masahiko Watanabe; Catherine Ledent; Gábor Juhász; Tamás F Freund; Zsófia Maglóczky
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.